Transdermal Patches That Must Be Removed Before MRI

AUGUST 25, 2016
This article was collaboratively written with Festus Durugo, a fourth-year PharmD candidate at Chicago State University College of Pharmacy.

Magnetic resonance imaging (MRI) is an important tool for diagnosing and evaluating diseases. The process can be summarized as induction of protons by a magnetic field, followed by excitation with radio frequency pulses and subsequent readout with receiver coils.1 

Thorough screening of each patient for any implantable devices and foreign bodies, pregnancy, and other potential issues is mandatory prior to scanning. Although MRI’s capabilities are well-recognized, its inherent dangers can’t be overlooked.

One report from the Joint Commission showed burns are the most common injuries in the MRI suite.The most common objects to undergo significant heating are wires and leads, pulse oximeter sensors and cables, and safety pins and metal clamps. Others include drug-delivery patches (which may contain a metallic coil), cardiorespiratory cables, and tattoos (which may contain iron oxide pigment).

In another study, MRI-related incidence was significantly higher in inpatient settings compared with outpatient centers (74% vs 29%).3 Additionally, medication safety was reported as the third-most frequent safety incident.

Transdermal patches are self-contained discrete dosage forms that deliver drugs through the skin to the systemic circulation.4 Their structural elements include:
  1. Backing layer,
  2. Drug layer or reservoir,
  3. Adhesive layer, and
  4. Protective or release liner.
In some instances, the drug and penetration enhancers or solubilizers are included in the adhesive layer. In other cases, the drug in a reservoir with penetration enhancers/solvents is incorporated into a microporous or dense polymeric membrane, followed by an adhesive layer for skin contact.

Some transdermal patches containing aluminum or other metal in their nonadhesive backing shouldn’t be worn during MRI because of skin burn risk. Health care professionals should advise patients wearing medication patches about procedures for proper removal and disposal before MRI and replacement afterwards.1,5 The FDA is currently reviewing transdermal products containing metal (Table6) to ensure they carry a warning about burn risk during MRI.

Pharmacists can play an important role by being familiar with these patches and ensuring they’re dispensed with the right auxiliary labels, removed appropriately before MRI, and correctly replaced afterwards. As the FDA continues to work with manufacturers to ensure proper labelling of transdermal patches with metal backing, pharmacists should know the FDA’s list of transdermal patches needing to be removed before MRI was last updated in 2009. Therefore, pharmacists should refer to package inserts for proper guidance, as new prescription, generic, and even OTC products aren’t included in the FDA’s original list. 

Table: Transdermal Patches That Must Be Removed Before MRI6
Generic Name Brand Name Delivery System Comments
Clonidine Catapres-TTS Reservoir •   Remove before MRI
•   Reapply same patch to another site afterwards
Diclofenac Flector Matrix •    Remove before MRI
•    Reapply same patch afterward if <2 hours have elapsed since patch was removed
•    Apply new patch if longer
Estradiol Alora
Matrix •    Remove before MRI
•     For reapplication after the procedure, follow same instructions as for patch falling off
Matrix •    Remove before MRI
Vivelle Dot Matrix •    Removal before MRI is recommended because manufacturer can’t guarantee product  doesn’t contain metal
Fentanyl Duragesic Matrix •    Remove before MRI
•    After procedure, apply a new patch to an alternate site
Lidocaine and Tetracaine Synera Thin uniform drug layer with oxygen-activated
heating component
•    Remove before MRI
Methyl Salicylate and Menthol Salonpas Matrix •    OTC product
•    Remove before MRI
•    Replace with fresh patch after procedure
Nicotine Nicoderm CQ
Reservoir •    To avoid confusion, recommend removing patch, regardless clear or opaque, before MRI
•    Reapply same patch after procedure
Oxybutynin Oxytrol Matrix •    Removal before MRI is recommended because manufacturer can’t guarantee product doesn’t contain metal
Rivastigmine Exelon Matrix •    Consider removal before MRI
•    Patch hasn’t been studied in patients undergoing MRI
Rotigotine Neupro Matrix •    Remove before MRI or cardioversion
Selegiline Emsam Matrix •    Remove before MRI because manufacturer can’t guarantee patch doesn’t contain metal
Scopolamine Transderm Scop Reservoir •    Remove before MRI
•    Place new patch on an alternate site following procedure
Testosterone Androderm Reservoir •    Remove before MRI
•    For reapplication after the procedure, follow same instructions as for patch falling off

1. Chernoff D, et al. Principles of magnetic resonance imaging. UpToDate. Waltham, MA. 2016
2. The Joint Commission. Preventing accidents and Injuries in the MRI suite. Updated February 18, 2008. Accessed August 25, 2016.
3.  Mansouri M, et al. Rates of safety incidence reporting in MRI in a large academic medical center. J Magn Reson Imaging. 2016;43:998-1007.                                                          
4.  Mitra AK, et al. Burns in MRI patients wearing transdermal drug delivery systems. Updated August 28, 2008. Accessed August 25, 2016.
5. Kuehn B. FDA warning: remove drug patches before MRI to prevent burns to skin. JAMA. 2009;301(13):1328
6. PL Technician Tutorial. dispensing the right patch with the right instructions. Pharmacist/Pharmacy Technician’s Letter. August 2016.

Alexander Kantorovich, PharmD, BCPS
Alexander Kantorovich, PharmD, BCPS
Alexander Kantorovich, PharmD, BCPS, is a Clinical Assistant Professor of Pharmacy Practice at Chicago State University College of Pharmacy and Clinical Pharmacy Specialist in the area of Internal Medicine at Advocate Christ Medical Center in Oak Lawn, Illinois. Dr. Kantorovich earned his Associate of Science degree with an emphasis in chemistry from William Rainey Harper College in 2008 and received his Doctor of Pharmacy degree in 2012 from the University of Illinois at Chicago College of Pharmacy. He went on to complete a 2-year pharmacotherapy residency with an emphasis in cardiology and critical care at the Cleveland Clinic and earned board certification in pharmacotherapy in 2014. His research interests center around cardiovascular pharmacotherapy, anticoagulation, and anticoagulation reversal.
Pharmacy Times Strategic Alliance

Pharmacist Education
Clinical features with downloadable PDFs

Personalize the information you receive by selecting targeted content and special offers.